Background: The detection of diagnostic autoantibodies such as antinuclear antibodies (ANA), anti-smooth muscle antibodies (SMA), anti-liver/kidney microsomal type 1 (anti-LKM1), anti-liver cytosol type 1 (anti-LC1) and anti-soluble liver antigen (anti-SLA) is historically associated with the diagnosis of autoimmune hepatitis. Key Messages: When autoimmune hepatitis is suspected, the detection of one or any combination of diagnostic autoantibodies, by indirect immunofluorescence or immuno-enzymatic techniques with recombinant antigens, is a pivotal step to reach a diagnostic score of probable or definite autoimmune hepatitis. Conclusions: Diagnostic autoantibodies (ANA, SMA, anti-LKM1, anti-LC1, anti-SLA) are a cornerstone in the diagnosis of autoimmune hepatitis. Other ancillary autoantibodies, associated with peculiar clinical correlations, appear to be assay-dependent and institution-specific, and validation studies are needed.

Keywords:
Liver, ELISA, Immunofluorescence, Assay
1.
Manns MP, Czaja AJ, Gorham JD, et al: Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51:2193-2213.
2.
Zachou K, Muratori P, Koukoulis GK, et al: Review article: autoimmune hepatitis - current management and challenges. Aliment Pharmacol Ther 2013;38:887-913.
3.
van Gerven NM, Verwer BJ, Witte BI, et al: Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol 2013;58:141-147.
4.
Hennes EM, Zeniya M, Czaja AJ, et al: Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48:169-176.
5.
Homberg JC, Abuaf N, Bernard O, et al: Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of ‘autoimmune' hepatitis. Hepatology 1987;7:1333-1339.
6.
Martini E, Abuaf N, Cavalli F, Durand V, Johanet C, Homberg JC: Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 1988;8:1662-1666.
7.
Alvarez F, Berg PA, Bianchi FB, et al: International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-938.
8.
Han S, Tredger M, Gregorio GV, Mieli-Vergani G, Vergani D: Anti-liver cytosolic antigen type 1 (LC1) antibodies in childhood autoimmune liver disease. Hepatology 1995;21:58-62.
9.
Ma Y, Okamoto M, Thomas MG, et al: Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002;35:658-664.
10.
Villalta D, Girolami E, Alessio MG, et al: Autoantibody profiling in a cohort of pediatric and adult patients with autoimmune hepatitis. J Clin Lab Anal 2014, Epub ahead of print.
11.
Maggiore G, Bernard O, Homberg JC, et al: Liver disease associated with anti-liver-kidney microsome antibody in children. J Pediatr 1986;108:399-404.
12.
Maggiore G, Veber F, Bernard O, et al: Autoimmune hepatitis associated with anti-actin antibodies in children and adolescents. J Pediatr Gastroenterol Nutr 1993;17:376-381.
13.
Gregorio GV, Portmann B, Reid F, et al: Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997;25:541-547.
14.
Muratori P, Granito A, Quarneti C, et al: Autoimmune hepatitis in Italy: the Bologna experience. J Hepatol 2009;50:1210-1218.
15.
Muratori P, Lalanne C, Fabbri A, Cassani F, Lenzi M, Muratori L: Type 1 and type 2 autoimmune hepatitis in adults share the same clinical phenotype. Aliment Pharmacol Ther 2015;41:1281-1287.
16.
Czaja AJ: Autoantibody-negative autoimmune hepatitis. Dig Dis Sci 2012;57:610-624.
17.
Dubois-Galopin F, Beauvillain C, Dubois D, et al: New markers and an old phenomenon: prozone effect disturbing detection of filaggrin (keratin) autoantibodies. Ann Rheum Dis 2007;66:1121-1122.
18.
Linder E, Miettinen A: Prozone effects in indirect immunofluorescence. Scand J Immunol 1976;5:513-519.
19.
Muratori L, Cataleta M, Muratori P, Lenzi M, Bianchi FB: Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut 1998;42:721-726.
20.
Bridoux-Henno L, Maggiore G, Johanet C, et al: Features and outcome of autoimmune hepatitis type 2 presenting with isolated positivity for anti-liver cytosol antibody. Clin Gastroenterol Hepatol 2004;2:825-830.
21.
Couto CA, Bittencourt PL, Porta G, et al: Antismooth muscle and antiactin antibodies are indirect markers of histological and biochemical activity of autoimmune hepatitis. Hepatology 2014;59:592-600.
22.
Gregorio GV, McFarlane B, Bracken P, Vergani D, Mieli-Vergani G: Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease. Autoimmunity 2002;35:515-519.
23.
Baeres M, Herkel J, Czaja AJ, et al: Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002;51:259-264.
24.
Miyakawa H, Kawashima Y, Kitazawa E, et al: Low frequency of anti-SLA/LP autoantibody in Japanese adult patients with autoimmune liver diseases: analysis with recombinant antigen assay. J Autoimmun 2003;21:77-82.
25.
Efe C, Ozaslan E, Wahlin S, et al: Antibodies to soluble liver antigen in patients with various liver diseases: a multicentre study. Liver Int 2013;33:190-196.
26.
Bogdanos DP, Mieli-Vergani G, Vergani D: Autoantibodies and their antigens in autoimmune hepatitis. Semin Liver Dis 2009;29:241-253.
27.
Zachou K, Rigopoulou E, Dalekos GN: Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. J Autoimmune Dis 2004;1:2.
28.
Vergani D, Alvarez F, Bianchi FB, et al: Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the international autoimmune hepatitis group. J Hepatol 2004;41:677-683.
29.
Floreani A, Liberal R, Vergani D, Mieli-Vergani G: Autoimmune hepatitis: contrasts and comparisons in children and adults - a comprehensive review. J Autoimmun 2013;46:7-16.
30.
Granito A, Muratori P, Quarneti C, Pappas G, Cicola R, Muratori L: Antinuclear antibodies as ancillary markers in primary biliary cirrhosis. Expert Rev Mol Diagn 2012;12:65-74.
31.
Granito A, Muratori L, Muratori P, et al: Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. J Clin Pathol 2006;59:280-284.
32.
Granito A, Muratori P, Muratori L, Georgios P, Lenzi M, Bianchi FB: Antifilamentous actin antibodies by ELISA for the diagnosis of type 1 autoimmune hepatitis. Am J Gastroenterol 2007;102:1131-1132.
33.
Gueguen M, Meunier-Rotival M, Bernard O, Alvarez F: Anti-liver kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily. J Exp Med 1988;168:801-806.
34.
Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF: Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest 1989;83:1066-1072.
35.
Lapierre P, Hajoui O, Homberg JC, Alvarez F: Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology 1999;116:643-649.
36.
Muratori L, Sztul E, Muratori P, et al: Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody type 1. Hepatology 2001;34:494-501.
37.
Wies I, Brunner S, Henninger J, et al: Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000;355:1510-1515.
38.
Costa M, Rodríguez-Sánchez JL, Czaja AJ, Gelpí C: Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype-1 autoimmune hepatitis. Clin Exp Immunol 2000;121:364-374.
39.
Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Büschenfelde KH: Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987;1:292-294.
40.
Zhang WC, Zhao FR, Chen J, Chen WX: Meta-analysis: diagnostic accuracy of antinuclear antibodies, smooth muscle antibodies and antibodies to a soluble liver antigen/liver pancreas in autoimmune hepatitis. PLoS One 2014;9:e92267.
41.
Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB: Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 1996;24:1068-1073.
42.
Zachou K, Oikonomou K, Renaudineau Y, et al: Anti-α actinin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1. Aliment Pharmacol Ther 2012;35:116-125.
43.
Czaja AJ, Shums Z, Binder WL, Lewis SJ, Nelson VJ, Norman GL: Frequency and significance of antibodies to chromatin in autoimmune hepatitis. Dig Dis Sci 2003;48:1658-1664.
44.
Montano-Loza AJ, Shums Z, Norman GL, Czaja AJ: Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int 2012;32:85-92.
45.
Miyake Y, Yamamoto K, Matsushita H, et al: Multicenter validation study of anti-programmed cell death-1 antibody as a serological marker for type 1 autoimmune hepatitis. Hepatol Res 2014;44:1299-1307.
46.
Matsumoto K, Miyake Y, Matsushita H, et al: Anti-programmed cell death-1 antibody as a new serological marker for type 1 autoimmune hepatitis. J Gastroenterol Hepatol 2014;29:110-115.
47.
Muratori L, Granito A, Muratori P, Pappas G, Bianchi FB: Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value. Clin Liver Dis 2008;12:261-276; vii.
48.
Muratori L, Cassani F, Pappas G, et al: The hepatitic/cholestatic ‘overlap' syndrome: an Italian experience. Autoimmunity 2002;35:565-568.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.